PubMed Journals Articles About "Kevin Sullivan Discusses Treatment Expansion Lung Cancer" RSS

10:45 EST 17th January 2020 | BioPortfolio

Kevin Sullivan Discusses Treatment Expansion Lung Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Kevin Sullivan Discusses Treatment Expansion Lung Cancer articles that have been published worldwide.

More Information about "Kevin Sullivan Discusses Treatment Expansion Lung Cancer" on BioPortfolio

We have published hundreds of Kevin Sullivan Discusses Treatment Expansion Lung Cancer news stories on BioPortfolio along with dozens of Kevin Sullivan Discusses Treatment Expansion Lung Cancer Clinical Trials and PubMed Articles about Kevin Sullivan Discusses Treatment Expansion Lung Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kevin Sullivan Discusses Treatment Expansion Lung Cancer Companies in our database. You can also find out about relevant Kevin Sullivan Discusses Treatment Expansion Lung Cancer Drugs and Medications on this site too.

Showing "Kevin Sullivan Discusses Treatment Expansion Lung Cancer" PubMed Articles 1–25 of 44,000+

Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer.

In the United States, lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Because no cure exists for advanced lung cancer, the primary treatment goal is to prolong survival.

Increased risk of coronary heart disease and stroke in lung cancer survivors: A Korean nationwide study of 20,458 patients.

With advances in lung cancer treatments, the number of lung cancer survivors has increased. As cardiovascular diseases (CVD) are some of the major causes of non-cancer deaths, CVD management is an integral part of cancer survivorship care. However, there is sparsity of data on cardiovascular risk in lung cancer survivors who underwent lung cancer surgery. We aimed to compare the incidence of CVD between lung cancer survivors and the general non-cancer population.

Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.

Identifying new predictive biomarkers in lung cancer that will prolong survival for additional subgroups of patients is of utmost importance. We report response to treatment and survival among homologous recombination deficient (HRD) lung cancer patients mostly BRCA mutation carriers to better define the predictive value of HRD status among non-small cell lung cancer (NSCLC).

Lung Cancer in Nonelderly Patients: Facility and Patient Characteristics Associated With Not Receiving Treatment.

In elderly patients with lung cancer, race/ethnicity is associated with not receiving treatment; however, little attention has been given to nonelderly patients (aged ≤65 years) with a range of disease stages and histologies. Nonelderly patients with lung cancer have superior survival at NCI-designated Comprehensive Cancer Centers (CCCs), although the reasons remain unknown.

Upregulation of E-cadherin in bronchoalveolar lavage fluid-derived exosomes in patients with lung cancer.

Lung cancer features extremely high rates of morbidity and mortality. Bronchoalveolar lavage fluid (BALF), obtained by bronchoscopy and bronchoalveolar perfusion, can provide information on the cellular components of the lung microenvironment to assist with diagnosis and treatment of lung cancer.

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.

Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such pa...

Antimicrobial peptides as novel therapeutics for nonsmall cell lung cancer.

Lung cancer is the second most common cancer in both men and women. Of all the lung cancer cases reported, 85% are nonsmall cell lung cancer (NSCLC). Although current treatments have improved the overall survival rate, success is limited, with serious treatment-related adverse effects reported. In addition, an increase in drug-resistant cancer cells limits the available treatment options. Antimicrobial peptides (AMPs) have gained much interest as anticancer drugs because they can selectively kill cancer cel...

The impact of severe mental illness on lung cancer mortality of patients with lung cancer in Finland in 1990-2013: a register-based cohort study.

Although the link between severe mental illness (SMI) and elevated cancer mortality is well established, few studies have examined lung cancer survival and SMI in detail. Our study compared cancer-specific mortality in patients with lung cancer with and without a history of SMI and analysed whether mortality differences could be explained by cancer stage at presentation, comorbidity or differences in cancer treatment.

The pathway to diagnosis and treatment for surgically managed lung cancer patients.

Most lung cancer is diagnosed at an advanced stage, resulting in poor survival. This study examined diagnostic pathways for patients with operable lung cancer to identify factors contributing to early diagnosis.

Real-world guideline-based treatment of lung cancer improves short- and long-term outcomes and resection rate: A population-based study.

Recent guidelines for the treatment of lung cancer include comprehensive lists of recommendations for pre-operative risk evaluation, staging, and surgery. Our aim was to evaluate whether the implementation of these in a population-based real-world setting would improve outcomes.

Translation and cultural adaptation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer Module for quality of life assessment in patients with lung cancer in Brazil.

To translate the European Organisation for Research and Treatment of Cancer (EORTC) 29-item Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC29, developed for the assessment of quality of life in patients with lung cancer) to Portuguese, conducting a pilot study of the Portuguese-language version and adapting it for use in Brazil.

Lung cancer surgical treatment after solid organ transplantation: A single center 30-year experience.

Solid organ transplantation is an accepted treatment for end-stage organ failure. Long-lasting immunosuppressive therapy may increase the risk ofde novo malignancies in transplant recipients. Increased risk of bronchogenic carcinoma in this population is controversial but prolonged transplant recipients' survival (obtained in modern transplantation era) may increase the need for lung cancer surgical resection in immunosuppressed patients. Our aim was to assess morbidity, mortality and long-term survival aft...

Tissue ACE phenotyping in lung cancer.

Pulmonary vascular endothelium is the main metabolic site for Angiotensin I-Converting Enzyme (ACE)-mediated degradation of several biologically-active peptides (angiotensin I, bradykinin, hemo-regulatory peptide Ac-SDKP). Primary lung cancer growth and lung cancer metastases decrease lung vascularity reflected by dramatic decreases in both lung and serum ACE activity. We performed precise ACE phenotyping in tissues from subjects with lung cancer.

Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.

American Indians and Alaska Natives (AI/AN) continue to experience extreme lung cancer health disparities. The state of Minnesota is home to over 70,000 AI/AN, and this population has a 2-fold increase in lung cancer mortality compared to other races within Minnesota. Genetic mutation testing in lung cancer is now a standard of high-quality lung cancer care, and EGFR mutation testing has been recommended for all adenocarcinoma lung cases, regardless of smoking status. However, genetic testing is a controver...

Complex segmentectomy in the treatment of stage IA non-small-cell lung cancer.

Although segmentectomy for lung cancer has been widely accepted, complex segmentectomy, which creates several, intricate intersegmental planes, remains controversial. Potential arguments include risk of incurability and 'failure of cancer control'. We compared the outcomes of complex segmentectomy versus lobectomy and evaluated its use in lung cancer treatment.

Development of thyroid carcinoma during treatment with pembrolizumab in a lung cancer patient.

Pembrolizumab, a programmed death 1 (PD-1) inhibitor, has been shown to have clinically significant efficacy in different types of cancer, providing long-term survival benefit for patients with lung cancer. Herein, we report the development of a primary thyroid cancer in a lung cancer patient that was being treated with pembrolizumab. Primary thyroid malignancy (and not only metastatic disease or immunotherapy-induced thyroiditis) should be considered in lung cancer patients being treated with immune checkp...

DIAPH3 promotes the tumorigenesis of lung adenocarcinoma.

Aberrant activation of MEKK-MEK-ERK signaling is frequently observed in lung cancer. Several inhibitors, which target this pathway, have shown clinical potential for the lung cancer treatment. Better understanding the regulation of this pathway would help the development of treatment strategies. In this study, we have identified the DIAPH3 as an up-regulated gene in lung adenocarcinoma. DIAPH3 promoted the growth of lung cancer cells both in the liquid culture and in the soft agar, and knockdown DIAPH3 inhi...

N-Phase Local Expansion Ratio for Characterizing Out-of-Phase Lung Ventilation.

Out-of-phase ventilation occurs when local regions of the lung reach their maximum or minimum volumes at breathing phases other than the global end inhalation or exhalation phases. This paper presents the N-phase local expansion ratio (LERN) as a surrogate for lung ventilation. A common approach to estimate lung ventilation is to use image registration to align the end exhalation and inhalation 3DCT images and then analyze the resulting correspondence map. This 2-phase local expansion ratio (LER2) is limite...

Hospital Variation in spending for Lung Cancer Resection in Medicare Beneficiaries.

As cancer payment models transition from fee-for-service towards payment "bundles" based on episodes of care, a deeper understanding of the costs associated with stage I lung cancer treatment becomes increasingly relevant. To better understand costs in early lung cancer care, we sought to characterize hospital-level variation in Medicare expenditure following lobectomy for stage I non-small cell lung carcinoma (NSCLC).

Lung Cancer Detection using Probabilistic Neural Network with modified Crow-Search Algorithm.

Lung cancer is a type of malignancy that occurs most commonly among men and the third most commontype of malignancy among women. The timely recognition of lung cancer is necessary for decreasing the effect ofdeath rate worldwide. Since the symptoms of lung cancer are identified only at an advanced stage, it is essential topredict the disease at its earlier stage using any medical imaging techniques. This work aims to propose a classificationmethodology for lung cancer automatically at the initial stage.

Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.

Lung cancer is the leading cause of cancer-related mortality worldwide. Treatment with immunotherapy has made a significant impact on the outcomes for those patients suffering from lung cancer and its usage is currently an established treatment modality. Immune checkpoint inhibition that has blocking antibodies which target cytotoxic T-lymphocyte antigen-4 (CTLA-4) along with the programmed cell death protein 1 (PD-1) pathway [programmed death - 1/programmed death-ligand 1 (PD-L1)] have shown promising resu...

Recent advances in biosensor for detection of lung cancer biomarkers.

Lung cancer is primary cancer threatening human life worldwide with the highest mortality rate. The early detection of lung cancer plays a critical role in the early diagnosis and subsequent treatment. However, the conventional methodologies limit the applications due to the low sensitivity, being expensive, and invasive procedure. Tumor markers as biochemical parameters can reflect cancer occurrence and progression, which show sensitivity, convenience, and low cost in developing biosensors, and act as good...

PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer.

The treatment paradigm of stage III, unresectable non-small cell lung cancer (NSCLC) has had few advancement since concurrent chemoradiotherapy was established as standard of care treatment. Despite modifications to radiotherapy, chemotherapy and surgical approaches, loco-regional and distant relapse remain high, which unfortunately has translated to poor survival outcomes. The PACIFIC study introduced immunotherapy to the domain of stage III NSCLC and has emerged as the fourth pillar in cancer treatment fo...

Analysis of survival for lung cancer resections cases with fuzzy and soft set theory in surgical decision making.

Lung cancer is the most common type of cancer around the world, and it represents the main cause of death in the USA. Surgical treatment is the optimal therapeutic strategy for resectable non-small cell lung cancer. The principal factor for long-term survival after complete resection is the anatomic extension of the neoplasm. However, other factors also have adverse effects on operative mortality, and influence long-term outcome. In this paper we propose an algorithmic solution for the estimation of 5-years...

Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death world-wide. Immune checkpoint inhibitors (ICI) have become the most promising type of treatment in oncology in general, and significantly so in NSCLC. Limited data is available about mechanisms of primary resistance. Data is lacking about mechanisms involved in acquired resistance or mixed responses in NSCLC. We aimed to identify mechanisms of resistance by studying biopsies taken from sites of secondary progression.

Quick Search